SCHEMBL7984878

SCHEMBL7984878

Oc1nc(-c2ccccc2F)nc2ncn(Cc3cccc(Cl)c3)c12

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.42
YTHDC1 Q96MU7 3/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
GLA P06280 1/20 0.41
HTT P42858 1/20 0.41
UBE2N P61088 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ACP1 P24666 2/20 0.40
MET P08581 1/20 0.39
CNR2 P34972 1/20 0.38
MAPK1 P28482 1/20 0.37
EGLN1 Q9GZT9 1/20 0.37
GAA P10253 1/20 0.37
HTR6 P50406 1/20 0.37
MAPT P10636 1/20 0.37
P2RX7 Q99572 1/20 0.37
FSCN1 Q16658 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7974646 0.90 MAPK14 (0.47) MAPK14SMN1; SMN2METMAPK1GAA
SCHEMBL7988454 0.89 MAPK14 (0.41) MAPK14UBE2NMETGAA
SCHEMBL7974309 0.88 CYP11B1 (0.45) MAPK14SMN1; SMN2HTTMETGAA
SCHEMBL7988184 0.86 MET (0.42) MAPK14SMN1; SMN2HTTL3MBTL1MET
SCHEMBL7985870 0.85 GAA (0.50) MAPK14YTHDC1L3MBTL1MAPK1GAA
SCHEMBL7988668 0.85 SMN1; SMN2 (0.44) YTHDC1SMN1; SMN2GLAHTTUBE2N
SCHEMBL7988817 0.84 SMN1; SMN2 (0.43) MAPK14YTHDC1SMN1; SMN2GLAHTT
SCHEMBL7992177 0.84 SMN1; SMN2 (0.42) YTHDC1SMN1; SMN2GLAHTTUBE2N
SCHEMBL7974060 0.84 SMN1; SMN2 (0.41) MAPK14SMN1; SMN2HTTL3MBTL1MET
SCHEMBL7973626 0.84 SMN1; SMN2 (0.45) YTHDC1SMN1; SMN2GLAHTTUBE2N

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6310070-B1 FOR TREATING NEPHRITIS, IMPROVING PROTEINURIA DUE TO GLOMERULONEPHRITIS AND PREVENTING AGGRAVATION OF NEPHRITIS JAPAN ENERGY CORPORATION (JP) 2001-10-30 US disclosed
EP-0999211-A1 NOVEL PURINE DERIVATIVES AND MEDICINAL USE THEREOF JAPAN ENERGY CORPORATION (JP) 2000-05-10 EP disclosed